Inaedis
Princeton, US · 2 known investors
Inaedis develops RTAD (Room Temperature Ambient Drying), a biopharmaceutical formulation platform that enables alternative drug delivery routes for monoclonal antibodies and biologics, including subcutaneous, inhaled, and intranasal administration. The platform reduces manufacturing risk and cost for pharmaceutical companies while improving patient access through room-temperature stability and simplified administration.
Founders & leadership
MM
Maksim MezhericherinFounder, CEO and CTO
HA
Howard A. StoneCo-Founder and CSO
Investors · 2
.jpeg){kind=logo}
Frequently asked questions
- What does Inaedis do?
- Inaedis develops RTAD (Room Temperature Ambient Drying), a biopharmaceutical formulation platform that enables alternative drug delivery routes for monoclonal antibodies and biologics, including subcutaneous, inhaled, and intranasal administration. The platform reduces manufacturing risk and cost for pharmaceutical companies while improving patient access through room-temperature stability and simplified administration.
- Who founded Inaedis?
- Inaedis was founded by Maksim Mezhericher, Howard A. Stone.
- Who are Inaedis's investors?
- Inaedis's investors include New Jersey Economic Development Authority, Roadrunner Ventures.
- Where is Inaedis headquartered?
- Inaedis is headquartered in Princeton, US.